Shore Now Offers TCAR Procedure to Treat Carotid Artery Disease & Prevent Stroke
Shore Medical Center now offers Transcarotid Artery Revascularization (TCAR), an FDA-cleared procedure to treat carotid artery disease and prevent stroke, with over 70,000 cases performed worldwide. Clinical trials demonstrate TCAR’s superiority, with a remarkably low periprocedural stroke rate of 1.4% in standard surgical risk, compared to 2.3% for carotid endarterectomy (CEA) and 4.1% for trans-femoral carotid artery stenting (TFCAS).
Moreover, TCAR reduces the relative risk of in-hospital and one-year stroke and death by nearly 50% compared to TFCAS. It’s availability at a hospital is associated with a 10% reduction in major adverse cardiovascular events at 30 days post-revascularization, whether TCAR or CEA.
Studies consistently show TCAR’s advantages over CEA, including lower risks of myocardial infarction and cranial nerve injury, shorter operating room and hospital stays, reduced clamp time, and the option for local anesthesia.
If you have patients with high-grade carotid stenosis, consider referring them for evaluation and potential TCAR intervention with Shore Physicians Group Vascular Surgeon Dr. Matthew Lawrence at Shore Medical Center. For more information contact Shore Physicians Group Division of General & Vascular Surgery at 609-365-6239. To learn more about TCAR, visit https://silkroadmed.com/healthcare-professionals/.
